Nasus Pharma Ltd SEC filings NSRX
Nasus Pharma Ltd has 100 filings in SEC EDGAR's recent list, going back to Aug 30, 2024. Its latest annual report, Form 20-F, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 8, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 11, 2026 | — |
| EFFECT | Filing | Aug 20, 2026 | — |
| EFFECT | Filing | Mar 31, 2026 | — |
| EFFECT | Filing | Mar 13, 2026 | — |
| CORRESP | Letter to the SEC | Mar 11, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 6, 2026 | — |
| D | Filing | Feb 25, 2026 | — |
| EFFECT | Filing | Aug 12, 2025 | — |
| CERT | Nyse american certification | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 8, 2025 | — |
| 8-A12B | Filing | Aug 8, 2025 | — |
| CORRESP | Letter to the SEC | Aug 7, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2025 | — |
| CORRESP | Letter to the SEC | Jul 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2025 | — |
| DRSLTR | Filing | May 21, 2025 | — |
| DRS/A | Filing | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| DRSLTR | Filing | May 12, 2025 | — |
| DRS/A | Filing | May 12, 2025 | — |
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| DRSLTR | Filing | Apr 29, 2025 | — |
| DRS/A | Filing | Apr 29, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 22, 2025 | — |
| DRSLTR | Filing | Apr 16, 2025 | — |
| DRS/A | Filing | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2025 | — |
| DRSLTR | Filing | Mar 21, 2025 | — |
| DRS/A | Filing | Mar 21, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 18, 2025 | — |
| DRS/A | Filing | Feb 6, 2025 | — |
| DRSLTR | Filing | Feb 5, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2025 | — |
| DRSLTR | Filing | Dec 31, 2024 | — |
| DRS/A | Filing | Dec 31, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2024 | — |
| DRS | Filing | Aug 30, 2024 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NSRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv - Yafo, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2029039
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.